Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental «gene silencing» therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.
Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%
Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.